

Demographic	Arm 1 (n=257)	Arm 2 (n=263)	Arm 3 (n=259)	Total (n=779)
Age, years	65 (59-70)	62 (54-68)	64 (55-69)	64 (56-69)
ECOG performance status				
0	105 (41)	113 (43)	93 (36)	311 (40)
1	122 (48)	123 (47)	135 (52)	380 (49)
2	28 (11)	27 (10)	31 (12)	86 (11)
Histological type				
High-grade serous carcinoma	199 (77)	185 (70)	194 (75)	578 (74)
Low-grade serous carcinoma	4 (2)	7 (3)	3 (1)	14 (2)
Serous (no grade specified) carcinoma	7 (3)	8 (3)	7 (3)	22 (3)
Clear cell	4 (2)	3 (1)	5 (2)	12 (2)
Endometrioid	1 (<1)	2 (1)	2 (1)	5 (1)
Mucinous	0	3 (1)	2 (1)	5 (1)
Mixed	2 (1)	3 (1)	3 (1)	8 (1)
Other	40 (16)	52 (20)	43 (17)	135 (17)
FIGO stage				
IC or IIA	1 (<1)	1 (<1)	2 (1)	4 (1)
IIB or IIC	3 (1)	4 (2)	1 (<1)	8 (1)
IIIA or IIIB	6 (2)	13 (5)	15 (6)	34 (4)
IIIC	177 (69)	171 (65)	159 (61)	507 (65)
IV	70 (27)	74 (28)	82 (32)	226 (29)
Number of NACT cycles received				
≤4 cycles	172 (67)	191 (73)	184 (71)	547 (70)
5/6 cycles	25 (10)	27 (10)	17 (7)	69 (11)
<i>Surgery not performed</i>	40 (16)	30 (11)	42 (16)	112 (14)
<i>Surgery data missing</i>	20 (8)	15 (6)	16 (6)	51 (7)

Table 1. Demographic data for patients undergoing neoadjuvant chemotherapy followed by delayed primary surgery. Data are presented as median (IQR) or number (%). Key: ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynaecology and Obstetrics; NACT, neoadjuvant chemotherapy; n, number. Arm 1 was three weekly carboplatin and paclitaxel, Arm 2 was three weekly carboplatin and weekly paclitaxel, Arm 3 was weekly carboplatin and weekly paclitaxel. An ECOG performance status of 0 equates to fully active, able to carry on all pre-disease performance without restriction; 1 equates to restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; and 2 equates to ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.

RECIST v1.1 response	Trial Arms			Total
	Arm 1	Arm 2	Arm 3	
Complete response	8 (4)	6 (3)	7 (4)	21 (4)
Partial response	102 (56)	119 (61)	106 (57)	327 (58)
Stable disease	61 (34)	60 (31)	62 (33)	183 (32)
Progressive disease	11 (6)	10 (5)	12 (6)	33 (6)
Non-measurable disease at baseline	29	27	29	85
Total (including non-measurable)	211	222	216	649
GCIG CA125 response*	Trial Arms			Total
	Arm 1	Arm 2	Arm 3	
Yes	198 (83)	204 (84)	208 (85)	610 (84)
No	42 (18)	39 (16)	36 (15)	117 (16)
Total	240	243	244	727

Table 2. RECIST v1.1 and GCIG CA125 response to neoadjuvant chemotherapy. Data presented as number (%) where % is column percentage (*Non-measurable disease at baseline* not included in denominator for RECIST v1.1 response). Arm 1 was three weekly carboplatin and paclitaxel, Arm 2 was three weekly carboplatin and weekly paclitaxel, Arm 3 was weekly carboplatin and weekly paclitaxel. Key: *All assessable patients had a pre-treatment CA125 of twice the upper limit of normal range.

		GCIG CA125 response			
		Yes	No	Missing	Total
RECIST v1.1	Complete response	18	1	2	21
	Partial response	287	23	17	327
	Stable disease	127	51	5	183
	Progressive disease	21	6	6	33
	Non-measurable disease at baseline	66	13	6	85
	<i>Missing</i>	<i>91</i>	<i>23</i>	<i>0</i>	<i>114</i>
	Total (including missing)	610	117	36	763

Table 3. RECIST v1.1 and GCIG CA125 response to neoadjuvant chemotherapy. Data are presented as number.

Outcome of cytoreductive surgery	RECIST v1.1 response					GCIG CA125 response		
	CR	PR	SD	PD	Total †	Yes	No	Total
Residual disease: 0 cm (complete/R0)	15 (75)	172 (55)	73 (42)	14 (48)	274 (51)	290 (50)	30 (30)	320 (47)
Residual disease: ≤1 cm (optimal)	3 (15)	77 (24)	44 (26)	3 (10)	127 (24)	145 (25)	19 (19)	164 (24)
Residual disease: >1 cm (suboptimal)	1 (5)	33 (10)	24 (14)	2 (7)	60 (11)	72 (13)	10 (10)	82 (12)
Inoperable (open and close surgery)	0	5 (2)	3 (2)	0	8 (1)	8 (1)	2 (2)	10 (1)
Surgery not performed	1 (5)*	28 (9)	28 (16)	10 (34)	67 (13)	61 (11)	40 (40)	101 (15)
<i>Surgery data missing</i>	<i>1</i>	<i>12</i>	<i>11</i>	<i>4</i>	<i>28</i>	<i>34</i>	<i>16</i>	<i>50</i>
Total (including missing)	21	327	183	33	564	610	117	727

Table 4. Outcome of cytoreductive surgery following neoadjuvant chemotherapy according to RECIST v1.1 and GCIG CA125 response. Data are presented as number (%) where % is column percentage (*Surgery data missing* not included in denominator). Key: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. *Reason stated by investigator as “clinical decision”; † Patients with RECIST v1.1 non-measurable disease were not included (n=85).